Home › NCT07848659

Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants

A Randomized, Double-blind, Placebo-controlled Crossover Study of the Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Single Doses of HBS 104 in Acutely Sleep-deprived Healthy Participants

Who can join

Ages 18 to 55 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Provide written informed consent before any study-related procedures are performed.
* Be healthy as determined by assessments at the Screening Visit.

Exclusion Criteria:

* Female with a positive pregnancy test at Screening Visit or upon check-in for Period 1.
* Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study and for 7 days after their final dose of study drug.

Note: Additional inclusion/exclusion criteria may apply, per protocol

About the study

This is a study to evaluate the pharmacodynamic effects, safety, tolerability, and pharmacokinetics of HBS-104 in acutely sleep-deprived healthy adult participants.

What is being tested

• HBS-104 (drug)
• Placebo (drug)

Sponsor: Harmony Biosciences Management, Inc. · Participants: 12 · Started: Aug 28, 2026

Contact the study team

• Clinical Trials Administrator · Phone: see email

Official record on ClinicalTrials.gov — NCT07848659

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.